Shafrin Defines Precision Medicine for U.S. News and World Report

In a new commentary for U.S. News and World Report, Jason Shafrin defines and elaborates on the field of precision medicine. Jason, IVI's Director of Research, illustrates how the United States is moving headlong into this new treatment approach. He notes some of the challenges while also emphasizing the unique hope precision medicine brings through [...]

2017-11-11T01:22:04-06:00August 25th, 2017|Viewpoints|

Sachs Provides an Overview of FDA User Fee Reauthorization Bill

In a recent post on the IVI-Sponsored Health Affairs blog series, Rachel Sachs provides an overview of the House of Representative's latest draft of the FDA user fee authorization bill. Sachs also examines changes in the bill from the earlier Senate markup, including incorporation of provisions from the bipartisan RACE Act and provides a possible [...]

2017-11-09T02:27:26-06:00July 13th, 2017|Viewpoints|

Sachs Summarizes Recent HELP Committee Meeting: The Elephant in the Room

In the latest post on the the IVI-sponsored Health Affairs blog series, Rachel Sachs summarizes the recent Senate Health, Education, Labor & Pensions (HELP) Committee meeting. Organized to address the drug delivery system and how it influences what patients pay, the meeting quickly shifted to a partisan blasting of the secretive process by which Republicans [...]

2017-07-14T05:22:13-06:00June 20th, 2017|Viewpoints|

Lietzan Examines SCOTUS Ruling on Biosimilars

In the latest post on the the IVI-sponsored Health Affairs blog series, Drugs and Medical Innovation, Erica Lietzan takes a look at the recent Supreme Court ruling on Sandoz v. Amgen, examining premarket patent litigation, patent resolution process, state law influence, and the impact of the SCOTUS ruling itself. Read the full article here.

2017-07-14T05:22:20-06:00June 19th, 2017|Viewpoints|

IVI’s Lakdawalla in WSJ: Look to Major League Baseball for Drug Pricing Insight

In a new commentary appearing in The Wall Street Journal, Dana Goldman and IVI Executive Director, Darius Lakdawalla, turn to the national pastime to provide a fresh perspective on the issue of drug pricing and the return on investment pharmaceutical companies need to sustain innovation. In baseball, the salaries are high and the talent pool is [...]

2017-07-18T22:26:51-06:00June 19th, 2017|Viewpoints|

Discussing the Challenges of Value-Based Pricing in STAT News

In a new commentary for STAT News, Anupam Jena (part of IVI's scientific advisory group) and Dana Goldman discuss the advantages of value-based pricing, pointing out several of the key challenges that complicate the application of health technology assessments. Jena and Goldman make the case that more transparency is needed and that an open-source model [...]

2017-07-18T22:27:01-06:00June 14th, 2017|Viewpoints|

Sood, Shih, Van Nuys and Goldman’s Study Details the Flow of Funds in Pharma’s Distribution System

In the latest post on the the IVI-sponsored Health Affairs blog series, Neeraj Sood, Tiffany Shih, Karen Van Nuys and Dana Goldman present the findings of their study examining the flow of funds in the pharmaceutical distribution system, suggesting that greater transparency and granularity would be beneficial in the reporting of financials from all sectors. [...]

2017-07-14T05:22:43-06:00June 13th, 2017|Viewpoints|

Grabowski and Manning Respond to a Recent Post by Yu, Helms, and Bach

In a post on the the IVI-sponsored Health Affairs blog series, Henry Grabowski and Richard Manning offer a rebuttal to a recent Health Affairs blog commentary by Nancy Yu, Zachary Helms, and Peter Bach on the subject of drug pricing. In their rebuttal, Grabowski and Manning caution that the premise of the earlier blog post [...]

2017-07-14T05:22:51-06:00June 2nd, 2017|Viewpoints|

Light Addresses the Pharma “Free Rider” Myth (in Response to Yu, Helms, and Bach)

In the latest post on the the IVI-sponsored Health Affairs blog series, Donald Light offers a response to a recent Health Affairs blog commentary by Nancy Yu, Zachary Helms, and Peter Bach focusing on the excess of US drug pricing over prices in other developed countries. Light argues that the myth of the "foreign free-rider," [...]

2017-07-14T05:22:57-06:00June 2nd, 2017|Viewpoints|

Carrier and Shadowen Propose Fixes for Pharma “Product Hopping”

In a recent post on the IVI-sponsored Health Affairs blog series, Michael Carrier and Steve Shadowen examine the practice of "product hopping," in which drug manufacturers can delay a generic introduction through product reformulation. In addition to presenting some of the prevailing issues before the courts, the authors also propose a new framework to keep the [...]

2017-07-14T05:23:04-06:00June 1st, 2017|Viewpoints|